A Randomized Double-blind, Parallel-group Study to Evaluate the Effect of BYDUREON Compared With Placebo on 24-hour Glucose Control in Metformin-treated Patients With Type 2 Diabetes
Phase of Trial: Phase IV
Latest Information Update: 04 Feb 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 11 Jun 2016 Results published in an AstraZeneca media release.
- 04 Apr 2016 Primary endpoint of change in 24-hour mean weighted glucose at week 4 and week 10 has been met, according to results presented at the 98th Annual Meeting of the Endocrine Society.